Shikonin inhibited mitogen-activated IL-4 and IL-5 production on EL-4 cells through downregulation of GATA-3 and c-Maf induction

Lee, Chen Chen; Kang, Jaw Jou; Chiang, Bor‐Luen; Wang, Chien Neng; Cheng, Yu Wen

doi:10.1016/j.lfs.2011.07.002

Cited by 17 publications

(11 citation statements)

References 47 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results demonstrated not only that shikonin at 0.3 µM is able to inhibit the in vitro maturation of dendritic cells but also that in vivo (4.5 µg, once daily for 5 days) it inhibits the allergic reaction and airway hyperresponsiveness in asthmatic mice. To gain insight into the mechanism of action of shikonin as an antiallergic drug, Lee et al [28] studied the effects of shikonin on TPA plus cAMP-induced Th2 cytokine production in activated EL-4 murine T-lymphoma cells. These cells produce IL-4 and IL-5 but not interferon-γ which is produced by Th2 cell-like cells and is responsible for allergic reactions.…”

Section: Shikonin In Autoimmune-mediated Inflammatory Diseasesmentioning

confidence: 99%

Pharmacological Properties of Shikonin – A Review of Literature since 2002

et al. 2013

View full text Add to dashboard Cite

!The naphthoquinone shikonin is the main active principle of Zicao, a traditional Chinese herbal medicine made from the dried root of Lithospermum erythrorhizon. Studies carried out over the past 30 years have provided a scientific basis for the use of Zicao which has been long employed in folk medicine to treat a variety of inflammatory and infectious diseases. In particular, shikonin has been shown to possess many diverse properties, including antioxidant, anti-inflammatory, antithrombotic, antimicrobial, and wound healing effects. The fact that shikonin shows so many beneficial properties has increased the interest in this molecule dramatically, especially in the past few years. The aim of this review is to provide an update of the new data published on shikonin, whose wide spectrum of pharmacological effects as well as pharmacokinetic properties and toxicity make it a highly interesting target molecule.

show abstract

Section: Shikonin In Autoimmune-mediated Inflammatory Diseasesmentioning

confidence: 99%

Pharmacological Properties of Shikonin – A Review of Literature since 2002

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Lung homogenates were separated with 10% SDS-PAGE gels, and electrophoresed proteins were transferred to a polyvinyldifluoride (PVDF) membrane to analyze the expression of specific target proteins, according to the method reported in a previous study [34]. The mouse monoclonal antibody to b-actin was purchased from Novus (Littleton, CO, USA) and rabbit polyclonal antibodies to VEGF-1 were purchased from Abcam.…”

Section: Western Blottingmentioning

confidence: 99%

Inhibition of high-mobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma

Lee

Lai

Chang

et al. 2013

Biochemical Pharmacology

Self Cite

View full text Add to dashboard Cite

“…Similarly, shikonin significantly prevented the clinical severity of allergic dermatitis. Several pharmacological mechanisms of shikonin against inflammation have been reported as follows: shikonin inhibits histamine release from human basophils through inhibition of Syk ‐dependent phosphorylation ; it inhibits NO production via inhibition of NO synthase induced by lipopolysaccharide in murine RAW 264.7 macrophages , and it inhibits the mitogen‐induced mRNA and protein expression of IL‐4 and IL‐5 in murine EL‐4 T lymphocytes . Furthermore, on DNA microarray analysis shikonin inhibited the expression of inflammatory molecules, notably cytokines (TNF‐α, IL‐1β and IL‐4), chemokines (macrophage inflammatory protein (MIP)‐1β and monocyte chemotactic protein (MCP)‐2), and inflammatory modulators (nuclear factor of activated T‐cells, cytoplasmic 3 (NFATC3) and prostaglandin‐endoperoxide synthase 2 (PTGS2)) in lipopolysaccharide‐stimulated human monocytic THP‐1 cells .…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of shikonin on skin lesions in mouse models of allergic dermatitis and wound

Kadoyama

Takenokuchi

Matsuura

et al. 2019

Traditional & Kampo Medicine

View full text Add to dashboard Cite

Aim: The aim of this study was to examine the beneficial effects of shikonin on skin lesions in mouse models of allergic dermatitis and wound. Methods: Mouse models of allergic dermatitis and wound were generated by spreading an allergic-inducing reagent on the dorsal skin and earflaps, and by punching the dorsal skin, respectively. The effects of shikonin on allergic dermatitis was evaluated on frequency of scratching, clinical severity of dermatitis and immunohistochemistry. The effect of shikonin on wound healing compared with steroid was evaluated by the size of the wound area. Results: Shikonin treatment not only improved allergic dermatitis, but also prevented the onset of allergic dermatitis. Furthermore, shikonin promoted wound healing in a mouse model of skin wound. In contrast, steroid (betamethasone) treatment, which is often applied to treat allergic dermatitis, delayed wound healing in the mouse model of allergic dermatitis. Conclusion: Shikonin can be used as a new therapeutic agent for the treatment of allergic dermatitis including atopic dermatitis.

show abstract

Shikonin inhibited mitogen-activated IL-4 and IL-5 production on EL-4 cells through downregulation of GATA-3 and c-Maf induction

Cited by 17 publications

References 47 publications

Pharmacological Properties of Shikonin – A Review of Literature since 2002

Pharmacological Properties of Shikonin – A Review of Literature since 2002

Inhibition of high-mobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma

Therapeutic effects of shikonin on skin lesions in mouse models of allergic dermatitis and wound

Contact Info

Product

Resources

About